The goal of this study is to use an online consensus method to identify key quality indicators measures of healthcare for substance use disorders in Alberta. We aim to develop a set of Quality Indicators to measure substance use disorder care. To achieve this, we will use online surveys to create a shortened list of quality indicators from those that are available (i.e. those identified in the scoping review).

This study examines how acute stress affects problem-solving and reward-related decision-making, focusing on how people adjust to new or changing situations. It also explores whether these effects differ between males and females. Participants will complete questionnaires and provide blood, saliva, and hair samples to measure stress-related responses. They will then perform tasks designed to test problem-solving and decision-making both before and after experiencing a stress-inducing situation.

The goal of our project is to evaluate the effects of parks visits for people living with dementia and their caregivers. The purpose of this project is to assess the effects of a park visit program on the quality of life, cognition, behavioral symptoms, stress, and burden in people living with dementia and their caregivers. We aim to recruit 10 people living with dementia and 10 caregivers. Participants who are selected for this study will be provided with education related to the health benefits of outdoor activities, resources to help them complete their outdoor activities, and weekly support sessions. Participants will then participate in outdoor activities of their choosing during their own time over 8 weeks. The park visiting program in-person assessments of participants with dementia and their caregivers will occur every 4 weeks during the project. This project will also provide families and healthcare providers with new approaches to help improve the quality of life of people affected by dementia.

CAN-PROTECT is an online study for people 18 and older that will look at things that contribute to healthy aging, as well as risk factors that contribute to a decline in memory, thinking, and dementia. We will also look at the contributors to health and stress in those who care for the people with dementia. Data will be collected online at www.canprotect.ca. The data that is collected will help the researchers to better understand the aging brain with a focus on the caregivers. It will also tell the burden on caregivers, and the factors that help and worsen this burden.

We want to hear your opinion! You will be asked to: - Complete a brief survey - Take part in a workshop or focus group to share your thoughts on how university's use student mental health data

Anxiety is a common concern that often begins in childhood or adolescence. Genetics play an important role in the likelihood a person will experience anxiety in their lifetime. Most studies looking at the genetics of anxiety have focused on adults. The aim of this study is to better understand the link between genetics and anxiety in young people ages 8-19.

We are testing a new treatment for suicidal thoughts and behaviors in youth (18-65 years of age). This study includes a 2-week treatment period. Participants will receive a therapy called repetitive transcranial magnetic stimulation (rTMS). This is a treatment that is Health Canada approved for depression in adults, and some research has shown that it decreases suicidal thoughts. Typically, this treatment is delivered once daily for 4-6 weeks, however we will condense the treatment by delivering two treatments per day to 'accelerate' the treatment. Here, we are trying to improve rTMS effectiveness by pairing it with a medication called cycloserine. Our research in adults suggests that this combination treatment is more effective than rTMS alone which is thought to be because cycloserine facilitates the brain's ability to respond to stimulation. Participants in this study will be randomly assigned to one of two groups. 1) rTMS+cycloserine and 2) rTMS+placebo. We will assess changes in suicidal thoughts and other measures of suicide risk immediately after 2-weeks of treatment. We will also ask you to return to the clinic 1-month and 6-months later for follow-up visits.

Background: Mood disorders like major depressive disorder and bipolar disorder make up a large part of the population. People with these disorders can experience a hard time with their mental health. They can also struggle with their physical health, and lifestyle. For many patients, current treatments rely on psychotherapy and pharmacotherapy. These treatments may be inaccessible or produce negative side effects. Currently, there is an increase in research which focuses on the microbiome-gut-brain axis. This is to develop different forms of treatment for mood disorders. Current readings shows that the gut plays an important role for the human body systems. Some of these systems are responsible for stress, anxiety, and depression. The treatments that this study will focus on promote healthy gut microbiota growth. This includes probiotics, prebiotics, dietary changes, and fecal microbiota transplantation (FMT). Patients have little awareness of, knowledge of, and misinformed attitudes towards MBT. This is due to some factors such as stigma. Other factors are satisfaction with current treatments, and lack of success of MBT. Many participants expressed their interest in learning more about the MBT. This was based on a previous study exploring patient perception of microbiome-based therapies. What is the study? This study offers a platform for those who are eager to learn more about the gut microbiome to educate themselves. This will be done through a series of short educational videos. The videos would be about 1-2 minutes long. What will the participant have to do? The participant’s knowledge and understanding will be tested with an assessment. The assessment will be taken before and after watching the videos. This is to measure the participant's knowledge before and after watching the videos.

We are interested in finding the cause of diseases of the heart and blood vessels that first show up in children and young adults. Many of these diseases are inherited, but we still do not know the cause in most cases. This study will use genetic testing to find these causes, followed by experiments in the lab to look at these changes in detail to see how they may cause the heart or blood vessel disease.

This study is looking at genetics, antidepressant medication, and side effects. Although antidepressants, such as selective-serotonin reuptake inhibitors (SSRIs), are often effective and well-tolerated in children and adolescents, some will have difficulty with side effects. One possible side effect is behavioral disinhibition. SSRI-induced behavioral disinhibition (SIBD) is characterized by a rapid onset of aggression, agitation, impulsivity, or hyperactivity following a start or increase in SSRI medication. This can result in socially inappropriate behavior and can lead to devastating consequences (e.g. suicidal impulses, violence). 10%–20% of children treated with SSRIs experience behavioral disinhibition. There is currently no way for doctors to predict which children will experience SIBD and other side effects. Knowing which genes could increase the chance of side effects with certain medications could give doctors and parents a simple, low cost, personalized tool for assessing risk and choosing a medication. This study is including children and adolescents who have taken an SSRI, both with and without side effects, to look for genes that may lead to side effects with certain medications. This is an exploratory study that will hopefully provide information to improve prescribing practices in the future.